136 related articles for article (PubMed ID: 38266622)
1. Recent advancements in the discovery of small-molecule non-nucleoside inhibitors targeting SARS-CoV-2 RdRp.
Zhou B; Chen D; Zhang T; Song C; Zhang X; Lin L; Huang J; Peng X; Liu Y; Wu G; Li J; Chen W
Biomed Pharmacother; 2024 Feb; 171():116180. PubMed ID: 38266622
[TBL] [Abstract][Full Text] [Related]
2. Identifying non-nucleoside inhibitors of RNA-dependent RNA-polymerase of SARS-CoV-2 through per-residue energy decomposition-based pharmacophore modeling, molecular docking, and molecular dynamics simulation.
Aziz S; Waqas M; Mohanta TK; Halim SA; Iqbal A; Ali A; Khalid A; Abdalla AN; Khan A; Al-Harrasi A
J Infect Public Health; 2023 Apr; 16(4):501-519. PubMed ID: 36801630
[TBL] [Abstract][Full Text] [Related]
3. Targeting the SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) with synthetic/designer unnatural nucleoside analogs: an in silico study.
Bag SS; Sinha S; Dutta S; Baishya HJ; Paul S
J Mol Model; 2023 Nov; 29(12):366. PubMed ID: 37950101
[TBL] [Abstract][Full Text] [Related]
4. Identifying Small-Molecule Inhibitors of SARS-CoV-2 RNA-Dependent RNA Polymerase by Establishing a Fluorometric Assay.
Bai X; Sun H; Wu S; Li Y; Wang L; Hong B
Front Immunol; 2022; 13():844749. PubMed ID: 35464436
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, docking, and biochemical characterization of non-nucleoside SARS-CoV-2 RdRp inhibitors.
Brindani N; Munafò F; Menichetti A; Donati E; Nigro M; Ottonello G; Armirotti A; De Vivo M
Bioorg Med Chem; 2023 Feb; 80():117179. PubMed ID: 36716583
[TBL] [Abstract][Full Text] [Related]
6. Identification of Polyphenol Derivatives as Novel SARS-CoV-2 and DENV Non-Nucleoside RdRp Inhibitors.
Gao S; Song L; Xu H; Fikatas A; Oeyen M; De Jonghe S; Zhao F; Jing L; Jochmans D; Vangeel L; Cheng Y; Kang D; Neyts J; Herdewijn P; Schols D; Zhan P; Liu X
Molecules; 2022 Dec; 28(1):. PubMed ID: 36615354
[TBL] [Abstract][Full Text] [Related]
7. Dynamics and binding affinity of nucleoside and non-nucleoside inhibitors with RdRp of SARS-CoV-2: a molecular screening, docking, and molecular dynamics simulation study.
Chinnamadhu A; Ramakrishnan J; Suresh S; Ramadurai P; Poomani K
J Biomol Struct Dyn; 2023 Dec; 41(20):10396-10410. PubMed ID: 36510678
[TBL] [Abstract][Full Text] [Related]
8. Plant-Derived Natural Non-Nucleoside Analog Inhibitors (NNAIs) against
Naidu SAG; Mustafa G; Clemens RA; Naidu AS
J Diet Suppl; 2023; 20(2):254-283. PubMed ID: 34850656
[TBL] [Abstract][Full Text] [Related]
9.
Patil SM; Martiz RM; Ramu R; Shirahatti PS; Prakash A; Chandra S J; Ranganatha VL
J Biomol Struct Dyn; 2022; 40(23):13032-13048. PubMed ID: 34632942
[TBL] [Abstract][Full Text] [Related]
10. Cyanorona-20: The first potent anti-SARS-CoV-2 agent.
Rabie AM
Int Immunopharmacol; 2021 Sep; 98():107831. PubMed ID: 34247016
[TBL] [Abstract][Full Text] [Related]
11. Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach.
Molavi Z; Razi S; Mirmotalebisohi SA; Adibi A; Sameni M; Karami F; Niazi V; Niknam Z; Aliashrafi M; Taheri M; Ghafouri-Fard S; Jeibouei S; Mahdian S; Zali H; Ranjbar MM; Yazdani M
Biomed Pharmacother; 2021 Jun; 138():111544. PubMed ID: 34311539
[TBL] [Abstract][Full Text] [Related]
12. De Novo Potent Peptide Nucleic Acid Antisense Oligomer Inhibitors Targeting SARS-CoV-2 RNA-Dependent RNA Polymerase via Structure-Guided Drug Design.
Shehzadi K; Yu M; Liang J
Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139312
[TBL] [Abstract][Full Text] [Related]
13. Plant-derived natural polyphenols as potential antiviral drugs against SARS-CoV-2
Singh S; Sk MF; Sonawane A; Kar P; Sadhukhan S
J Biomol Struct Dyn; 2021 Oct; 39(16):6249-6264. PubMed ID: 32720577
[TBL] [Abstract][Full Text] [Related]
14. Screening of Severe Acute Respiratory Syndrome Coronavirus 2 RNA-Dependent RNA Polymerase Inhibitors Using Computational Approach.
Dhankhar P; Dalal V; Kumar V
J Comput Biol; 2021 Dec; 28(12):1228-1247. PubMed ID: 34847746
[TBL] [Abstract][Full Text] [Related]
15. Identification of SARS-CoV-2 RNA dependent RNA polymerase inhibitors using pharmacophore modelling, molecular docking and molecular dynamics simulation approaches.
Pundir H; Joshi T; Pant M; Bhat S; Pandey J; Chandra S; Tamta S
J Biomol Struct Dyn; 2022; 40(24):13366-13377. PubMed ID: 34637693
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of potential anti-RNA-dependent RNA polymerase (RdRP) drugs against the newly emerged model of COVID-19 RdRP using computational methods.
Poustforoosh A; Hashemipour H; Tüzün B; Pardakhty A; Mehrabani M; Nematollahi MH
Biophys Chem; 2021 May; 272():106564. PubMed ID: 33711743
[TBL] [Abstract][Full Text] [Related]
17. Prediction of potential inhibitors for RNA-dependent RNA polymerase of SARS-CoV-2 using comprehensive drug repurposing and molecular docking approach.
Parvez MSA; Karim MA; Hasan M; Jaman J; Karim Z; Tahsin T; Hasan MN; Hosen MJ
Int J Biol Macromol; 2020 Nov; 163():1787-1797. PubMed ID: 32950529
[TBL] [Abstract][Full Text] [Related]
18. Potential Candidates against COVID-19 Targeting RNA-Dependent RNA Polymerase: A Comprehensive Review.
Agrawal N; Goyal A
Curr Pharm Biotechnol; 2022; 23(3):396-419. PubMed ID: 33882805
[TBL] [Abstract][Full Text] [Related]
19. A computational approach to drug repurposing against SARS-CoV-2 RNA dependent RNA polymerase (RdRp).
Ribaudo G; Ongaro A; Oselladore E; Zagotto G; Memo M; Gianoncelli A
J Biomol Struct Dyn; 2022 Feb; 40(3):1101-1108. PubMed ID: 32948103
[TBL] [Abstract][Full Text] [Related]
20. Lycorine, a non-nucleoside RNA dependent RNA polymerase inhibitor, as potential treatment for emerging coronavirus infections.
Jin YH; Min JS; Jeon S; Lee J; Kim S; Park T; Park D; Jang MS; Park CM; Song JH; Kim HR; Kwon S
Phytomedicine; 2021 Jun; 86():153440. PubMed ID: 33376043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
